Apple is one of the most bet against stocks in the market... kind of. We explain why it's true, but kind of a misleading stat.

GE’s CEO may have just retired, but he left the company perfectly positioned for a green-energy fueled future.

A Supreme Court decision that speeds biosimilar drugs to market makes investing in biosimilar stocks even more enticing.  

Discount supermarket chain Aldi will be investing billions in the U.S. market over the next five years, while its fellow German-based rival Lidl prepares to open its first U.S. locations this week. But the biggest winner from this growing competition will be the U.S. consumer.

The House of Representatives voted last week in favor of the Financial CHOICE Act, which is designed to roll back the enhanced regulatory regime laid out in the Dodd-Frank Act of 2010. On this episode of Industry Focus, we dig into the Financial CHOICE Act and discuss what this means for banks.

The average investor has a wealth of information at their fingertips, they just need to know where to find it. We talk about our favorite free tools and resources, and Michael Douglass explains why he thinks "the numbers obscure the true story."

Railroad stocks have consistently beaten the market – here’s why investors should give them a look today.

Bluebird bio, TG Therapeutics, and Loxo Oncology investors are smiling following bullish presentations for their respective cancer drugs at the annual American Society of Clinical Oncology conference this week.

Sponsored link: http://www.casper.com/fool code fool.

In its last private funding round, Blue Apron reached a valuation of over $2 billion. Now, the company has its sights set on the public market, and we are digging into the IPO filing to break down the financials and business model of meal kit delivery for investors.

Citizens Financial became the biggest bank stock IPO in history when it went public in 2014. Since then, it's orchestrated an impressive turnaround.

Sponsored link: http://www.casper.com/fool code fool.